Venture-Backed Dicerna Cuts First Pharma Deal as Prelude to 'B' Round
The startup takes preclinical money from Kyowa Hakko Kirin to target cancer with its alternative RNAi method.
The startup takes preclinical money from Kyowa Hakko Kirin to target cancer with its alternative RNAi method.